We are live on ! Find out more
GSK icon

GSK
GSK

1,031 hedge funds and large institutions have $20.7B invested in GSK in 2026 Q1 according to their latest regulatory filings, with 141 funds opening new positions, 315 increasing their positions, 381 reducing their positions, and 82 closing their positions.

New
Increased
Maintained
Reduced
Closed

72% more first-time investments, than exits

New positions opened: 141 | Existing positions closed: 82

63% more call options, than puts

Call options by funds: $222M | Put options by funds: $137M

36% more funds holding in top 10

Funds holding in top 10: 11 → 15 (+4)

5% more capital invested

Capital invested by funds: $19.6B → $20.7B (+$1.03B)

4% more funds holding

Funds holding: 995 → 1,031 (+36)

1.11% less ownership

Funds ownership: 19.53% → 18.42% (-1.1%)

17% less repeat investments, than reductions

Existing positions increased: 315 | Existing positions reduced: 381

Holders
1,031
Holders Change
+36
Holders Change %
+3.62%
% of All Funds
12.69%
Holding in Top 10
15
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+36.36%
% of All Funds
0.18%
New
141
Increased
315
Reduced
381
Closed
82
Calls
$222M
Puts
$137M
Net Calls
+$85.7M
Net Calls Change
-$49.4M

Top Buyers

1
Morgan Stanley
Morgan Stanley
New York
+$282M
2
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$154M
3
Goldman Sachs
Goldman Sachs
New York
+$127M
4
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$111M
5
BlackRock
BlackRock
New York
+$94.1M

Top Sellers

1
Dodge & Cox
Dodge & Cox
California
-$534M
2
JEST
JTC Employer Solutions Trustee
Jersey
-$292M
3
UBS Group
UBS Group
Switzerland
-$227M
4
Federated Hermes
Federated Hermes
Pennsylvania
-$145M
5
Holocene Advisors
Holocene Advisors
New York
-$141M
Name Holding Trade Value Shares
Change 		Change in
Stake
APW
1001
Aventura Private Wealth
Florida
$3.26K – – –
KFA
1002
Kelleher Financial Advisors
New York
$3.26K – – –
NF
1003
Napier Financial
Massachusetts
$3.2K +$3.14K +58 New
BSB
1004
Bangor Savings Bank
Maine
$3.15K -$34.4K -634 -92%
WA
1005
WPG Advisers
Maryland
$3.15K -$867 -16 -22%
BAM
1006
Byrne Asset Management
New Jersey
$3.09K – – –
NWS
1007
Nvest Wealth Strategies
Ohio
$2.98K +$325 +6 +13%
JFG
1008
JDM Financial Group
Texas
$2.87K +$2.82K +52 New
MSG
1009
Main Street Group
Virginia
$2.76K +$2.71K +50 New
SIS
1010
Strategic Investment Solutions
Illinois
$2.59K – – –
WA
1011
Westfuller Advisors
New York
$2.28K -$975 -18 -31%
VWA
1012
Valued Wealth Advisors
Utah
$2.04K +$2K +37 New
LAS
1013
Lloyd Advisory Services
Georgia
$1.99K -$146K -2,689 -99%
DWM
1014
Dogwood Wealth Management
Kansas
$1.99K +$1.95K +36 New
KFG
1015
Kingdom Financial Group
Arizona
$1.99K +$1.95K +36 New
AFC
1016
Ares Financial Consulting
California
$1.9K – – –
ECA
1017
Elevated Capital Advisors
Utah
$1.88K – – –
HIW
1018
Holos Integrated Wealth
Pennsylvania
$1.79K – – –
SIM
1019
Synergy Investment Management
Florida
$1.66K +$1.63K +30 New
RJA
1020
Ross\Johnson & Associates
Minnesota
$1.32K – – –
FFA
1021
Frazier Financial Advisors
Ohio
$1.16K -$3.2K -59 -74%
FG
1022
Fairman Group
Pennsylvania
$1.11K – – –
PUI
1023
Purpose Unlimited Inc
$1.05K -$5.58K -103 -84%
TFA
1024
Toth Financial Advisory
Virginia
$1.05K – – –
DB
1025
Danske Bank
Denmark
$607 – – –
39 40
41
42 43

GSK Hedge Fund Activity: Q1 2026 in Review

1,031 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q1 2026, worth a combined $20.7B — up 5.2% from $19.6B a quarter earlier.

Buyers outnumbered sellers: 141 funds opened new GSK positions and 82 closed out — a net gain of 59 holders — while 315 added to existing stakes and 381 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $282M. The largest seller was Dodge & Cox, cutting an estimated $534M.

  • 1,031 institutional investors held GSK (GSK) as of Q1 2026, up from 995 in Q4 2025.
  • Funds reported $20.7B of GSK stock for Q1 2026, up 5.2% quarter-over-quarter.
  • 141 funds opened new GSK positions in Q1 2026 and 82 closed out, a net change of +59 holders.
  • The largest GSK buyer in Q1 2026 was Morgan Stanley, an estimated $282M added.
  • The largest GSK seller in Q1 2026 was Dodge & Cox, an estimated $534M sold.

Based on aggregated 13F filings for Q1 2026.